• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Download Hennessy's Highlights® March 2024 edition

Feature
Article
Pharm Exec E-BooksHennessy's Highlights® March 2024
Volume eBook

Hennessy's Highlights® features the latest oncology news From Mike Hennessy Jr, President & CEO of MJH Life Sciences.

The March 2023 issue, available for download below, contains:

  • Early Phase Clinical Research Center Poised to Provide New Benefits in Hawaii and Beyond
  • Outreach and Engagement: Colleagues Come Together to Improve Community Care
  • Tampa General Hospital Cancer Institute Celebrates 2 Years of Growth and Innovation
  • Metrics Report: Which of Your Peers Are Trending?
Download Issue PDF
Articles in this issue
Tampa General Hospital Cancer Institute Celebrates 2 Years of Growth and Innovation
Tampa General Hospital Cancer Institute Celebrates 2 Years of Growth and Innovation
Outreach and Engagement: Colleagues Come Together to Improve Community Care
Outreach and Engagement: Colleagues Come Together to Improve Community Care
Early Phase Clinical Research Center Is Poised to Provide New Benefits in Hawaii and Beyond
Early Phase Clinical Research Center Is Poised to Provide New Benefits in Hawaii and Beyond
Download Hennessy's Highlights® March 2024 edition
Download Hennessy's Highlights® March 2024 edition
Recent Videos
Related Content
FDA Approves Dupixent as First-Ever Biologic Treatment for Chronic Obstructive Pulmonary Disease

FDA Approves Dupixent as First-Ever Biologic Treatment for Chronic Obstructive Pulmonary Disease

Don Tracy, Associate Editor
September 27th 2024
Article

Dupixent was found to significantly reduce the rate of moderate to severe exacerbations of chronic obstructive pulmonary disease, according to data from the Phase III BOREAS and NOTUS trials.

A Different Approach to Dermatology Care

A Different Approach to Dermatology Care

Miranda Schmalfuhs
September 23rd 2024
Podcast

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

Martin Gonzalez is a Principal of Org and Leadership Development at Google.

What is the Secret Sauce for Top School Graduates to Convert Start-Up Ideas into Sustainable Firms?

Michael Wong
September 27th 2024
Article

A Harvard Business School Healthcare Alumni Association Q&A with Martin Gonzalez, Principal of Org and Leadership Development at Google.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs
September 6th 2024
Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

John A. Murphy

AAM Names John A. Murphy as CEO

Mike Hollan
September 27th 2024
Article

Murphy previously worked at the Biotechnology Innovation Organization as its chief policy officer.

Stock.adobe.com

RxPreferred Launches AI-Powered Savings Program for Members

Mike Hollan
September 27th 2024
Article

The program, Rx-Performance, will be available starting in January of next year.